Does Your Insurance Cover
GLP-1 Medication?

In 2025–2026, many employers and insurers dropped weight-loss GLP-1 coverage due to rising costs. These medications can cost $900–$1,300/month per patient, and with millions seeking prescriptions, total spending became unsustainable for many plan sponsors. Some estimates suggest 41 million people lost Wegovy coverage in 2026 alone. Employers are reevaluating whether to cover weight-loss indications, though diabetes coverage remains largely intact.

Prior authorization (PA) is a requirement from your insurance company that your doctor get approval before prescribing a medication. Your doctor must submit clinical documentation showing you meet specific criteria — such as a certain BMI, a diabetes diagnosis, or evidence that other treatments were tried first. PA can take days to weeks and may be denied, requiring an appeal.

Step therapy (also called "fail first") requires you to try and fail on less expensive medications before your insurance will cover a more expensive one. For GLP-1s, this might mean trying metformin, sulfonylureas, or older diabetes drugs first. You must document that these alternatives didn't work (or caused side effects) before the insurer approves a GLP-1.

Medicare Part D covers GLP-1 medications prescribed for Type 2 diabetes — including Ozempic, Mounjaro, Rybelsus, and Trulicity. However, Medicare currently does not cover GLP-1 medications prescribed solely for weight loss. A pilot program for weight-loss coverage may begin in July 2026, but until then, Medicare beneficiaries needing weight-loss medications must pay out of pocket or use manufacturer programs.

Drug manufacturers offer savings cards and patient assistance programs to reduce your cost:

• Novo Nordisk (Ozempic, Wegovy, Rybelsus, Saxenda): NovoCare offers savings cards for commercially insured patients and patient assistance for uninsured/underinsured.
• Eli Lilly (Mounjaro, Zepbound, Trulicity): Lilly Cares offers similar programs, including the Mounjaro Savings Card for eligible patients.

Eligibility varies — most savings cards require commercial insurance and exclude government plans (Medicare, Medicaid, TRICARE).

Several options may help reduce costs:

• Manufacturer savings programs — Can reduce copays to as low as $25/month for eligible patients.
• DTC/Telehealth providers — Companies offering compounded GLP-1 medications at $149–$500/month.
• Patient assistance programs — Income-based programs from manufacturers for uninsured patients.
• Appeal insurance denials — Work with your doctor to file an appeal with supporting clinical documentation.
• Ask about alternatives — Your doctor may know of lower-cost options or clinical trials.